Visterra

visterrainc.com

Visterra is a biologics research and early-stage clinical development company focused on developing therapies for immune-mediated and hard-to-treat diseases. The company employs innovative technologies, including AI and computational methods, to create novel therapeutics, with a commitment to improving patient outcomes. Their lead program, Sibeprenlimab (VIS649), targets IgA nephropathy, showcasing their dedication to addressing significant medical needs. Visterra's unique approach combines a strong pipeline with a collaborative culture, positioning them as a promising player in the biopharmaceutical industry.